OCD drug tested to clear long COVID brain fog
NCT ID NCT05874037
Summary
This study tested whether fluvoxamine, a medication already approved for obsessive-compulsive disorder, could help improve symptoms of Long COVID like brain fog, trouble concentrating, anxiety, depression, and fatigue. It involved 191 adults from Missouri and Illinois who had been experiencing worsening cognitive symptoms for at least two months after a COVID-19 infection. Participants were randomly assigned to take either fluvoxamine or a placebo pill for 16 weeks to see if the drug reduced their symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.